CD274 and melanoma: Furthermore, a novel anti-PD-L1/CD3 nanobody-based BiTE demonstrates cytotoxic activity on melanoma cells correlated with PD-L1 expression levels, highlighting its potential in treating PD-L1-overexpressing melanoma.